Stock Deep Dive · 2026-07-24
Samsung Biologics (207940) closed at ₩1,518,000, up 10.08% on the day. Year-to-date return is -10.4%, sitting at 38% of its 52-week range. Listed in Seoul — for USD-based investors, KRW moves add an FX layer on top of the stock’s local return.
|
Close
₩1,518,000
+10.08% · YTD -10.4%
|
Market Cap
₩70.27T
Biotechnology
|
Forward P/E
30.9x
PER 37.4x
|
52-wk Range
38%
High ₩1,987,000 · Low ₩1,228,000
|
🔍 At a Glance
Samsung Biologics is having a strong month — up 10.6% today alone and +9.6% over one month — supported by 47.9% TTM operating margins and 25.8% YoY quarterly revenue growth, plus a “strong buy” consensus from 24 analysts (average target ₩2,020,333, well above the current ₩1,518,000). Yet the stock remains down 10.4% YTD and 20.4% over six months, trades at a rich 37.4x trailing PER and 22.8x EV/EBITDA, and at least one house (Meritz) has cut its target, warning that a rebound is “difficult without major orders.”
🏢 How It Makes Money
Samsung Biologics is the CDMO (contract development and manufacturing organization) arm of the Samsung group, based in Incheon and listed on the KOSPI. It earns fees across the biologics lifecycle — cell line development, process/analytical development, GMP manufacturing, aseptic fill-finish, and quality/regulatory testing — and is expanding into antibody-drug conjugates and mRNA. The just-announced all-cash acquisition of PolyPeptide (CHF 1.46bn / roughly $1.8bn) pushes the company into peptide manufacturing, broadening its multi-modality platform across the U.S., Europe, and India.
📈 Quarterly Results — Is Business Growing?
| Quarter | Revenue | Op. Income | Net Income | Op. Margin |
|---|---|---|---|---|
| 25Q1 | ₩999.5B | ₩430.2B | ₩375.6B | 43.0% |
| 25Q2 | ₩1.29T | ₩475.6B | ₩324.4B | 36.9% |
| 25Q3 | ₩1.66T | ₩728.8B | ₩574.5B | 43.9% |
| 25Q4 | ₩308.6B | ₩378.1B | ₩510.0B | 122.5% |
| 26Q1 | ₩1.26T | ₩580.8B | ₩469.2B | 46.2% |
Latest-quarter revenue up +25.8% versus the same quarter a year ago.
💡 Korea Market 101
⚖️ Valuation — Cheap or Expensive?
| Metric | Value | How to read it |
|---|---|---|
| P/E (trailing) | 37.4x | Price vs last 12 months’ earnings |
| P/E (forward) | 30.9x | Price vs next 12 months’ expected earnings — growth hopes baked in |
| P/S | 15.6x | Price vs revenue — for high-growth names with thin profits |
| P/B | 9.4x | Price vs book value — below 1x means priced under liquidation value |
| PEG | 2.1x | P/E ÷ growth — near 1 is fair for the growth; above 2 is demanding |
| EV/EBITDA | 22.8x | Enterprise value (incl. debt) vs cash generation |
Peer comparison
| Name | Mkt Cap | P/E | Fwd P/E | P/S |
|---|---|---|---|---|
| SAMSUNG BIOLOGICS | ₩70.27T | — | 30.9x | 14.6x |
| Celltrion | ₩40.73T | — | 24.3x | 9.1x |
💡 Korea Market 101
🎯 Street Consensus
- Price target (mean): ₩2,020,333
- Target high / low: ₩2,300,000 / ₩1,600,000
- Implied upside: +33.1%
- Rating: Strong Buy (1.4/5)
- Analysts covering: 24
💡 Korea Market 101
📉 Price Action — Technical Check
| Indicator | Value | How to read it |
|---|---|---|
| RSI (14d) | 59.1 | Above 70 overbought · below 30 oversold |
| vs 60-day MA | +9.3% | Above/below the medium-term trend |
| vs 200-day MA | -5.8% | Above/below the long-term trend |
| Golden/death cross | 50-day below 200-day (bearish alignment) | 50-day MA crossing above (golden) or below (death) the 200-day |
| Volume (vs 20d avg) | 3.5x | 2x+ means a spike in market attention |
💡 Korea Market 101
📰 Recent News
- Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India — PR Newswire
- Why is Samsung Biologics stock sliding today? By Investing.com — Investing.com Nigeria
- Meritz Securities Cuts Samsung Biologics Target to approximately $1,363, Says Rebound Difficult Without Major Orders — finance.biggo.com
- Samsung Biologics To Acquire PolyPeptide For CHF 1.46 Billion — Pulse 2.0
- Samsung Biologics to Acquire Peptide Group for $1.8 Billion (SMC — GuruFocus
- Samsung Biologics Acquires PolyPeptide Group for $1.8 Billion — Briefs Finance
💡 Korea Market 101
🔭 Scenarios & What to Watch
Bulls will watch for large new manufacturing contracts to validate the recent bounce and justify premium multiples (PEG 2.1, PBR 9.4). Bears should confirm PolyPeptide integration costs and financing terms don’t dilute the 47.9% margin profile. RSI at 59.1 and price still -5.8% versus MA200 suggest the trend is unsettled; USD-based investors should also monitor KRW moves. Next quarterly earnings will be key to assess order momentum.
💡 Korea Market 101
📚 All stock analysis · More on Samsung Biologics · Market report for this session
Stock report · published 2026-07-24 16:00 KST
For information only — a summary of public data, not a recommendation to buy or sell any security. Source data (Yahoo Finance and others) may be delayed or contain errors. All investment decisions are your own responsibility.
Leave a Reply